Skip to main content
TipRanks
Go Ultimate75% OFF

Ibio (IBIO) Stock Price & Analysis

2,329 Followers

IBIO Stock Chart & Stats

$0.85$0.10(13.37%)
At close: 4:00 PM EST
$0.75$1$1.25$1.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.75 - $0.87
52-Week Range
$0.68 - $3.82
Previous Close
$0.75
Volume
N/A
Average Volume (3M)
610.06K
Market Cap
$52.71M
Enterprise Value
$104.27M
Total Cash (Recent Filing)
$76.65M
Total Debt (Recent Filing)
$2.07M
Price to Earnings (P/E)
―
Beta
1.07
Next Earnings
Feb 16, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Pipeline Differentiation

The extended primate results support a potentially differentiated obesity therapy focused on fat-selective weight loss and lean-mass preservation. If later studies reproduce these effects, IBIO-610 could address an important limitation of existing treatments and strengthen iBio’s strategic position.

Revenue Rebound

The sharp TTM revenue rebound indicates improving commercial or partnership-related activity from a very small base. Although the scale remains limited, continued top-line expansion could provide a broader funding foundation and demonstrate progress beyond a purely research-stage operating profile.

Low Leverage

Very low leverage gives iBio more financial flexibility than a highly indebted biotechnology company. Limited debt obligations reduce pressure from interest and refinancing requirements, leaving management greater capacity to direct available resources toward pipeline development and future milestones.

Bears Say

Persistent Large Losses

The company has not yet demonstrated a sustainable profit model, and its losses remain extremely large relative to revenue. Persistent negative earnings can erode equity over time, constrain strategic flexibility, and increase dependence on external financing while products remain under development.

Continued Cash Burn

Negative operating and free cash flow show that iBio is not currently self-funding its operations. Continued cash consumption can require additional financing before the pipeline generates meaningful revenue, increasing pressure on capital allocation and potentially limiting development choices.

Preclinical Development Stage

The key pipeline assets have generated encouraging animal and laboratory findings but have not yet established human safety or efficacy. Their value therefore remains dependent on future clinical execution, regulatory progress, and the ability to translate preclinical results into viable therapies.

Ibio News

IBIO FAQ

What was Ibio’s price range in the past 12 months?
Ibio lowest stock price was $0.68 and its highest was $3.82 in the past 12 months.
What is Ibio’s market cap?
Ibio’s market cap is $52.71M.
When is Ibio’s upcoming earnings report date?
Ibio’s next earnings report is estimated for Feb 16, 2027 (not yet confirmed), which is in 89 days.
How were Ibio’s earnings last quarter?
Ibio released its earnings results on Nov 10, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.02.
Is Ibio overvalued?
According to Wall Street analysts Ibio’s price is currently Undervalued.
Does Ibio pay dividends?
Ibio does not currently pay dividends.
What is Ibio’s EPS estimate?
Ibio’s EPS estimate is -0.08.
How many shares outstanding does Ibio have?
Ibio has 70,455,810 shares outstanding.
What happened to Ibio’s price movement after its last earnings report?
Ibio reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went up 5.641%.
Which hedge fund is a major shareholder of Ibio?
Hedge funds hold Ibio shares: the largest hedge-fund position in Ibio is 72,394,659 shares, and hedge funds increased their holdings by 1.9M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology